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Abstract
Background: Various prognostic serum and cellular markers have been identified for many diseases, such as cardiovascular
diseases and tumor pathologies. Here we assessed whether the levels of certain stem cells may predict the progression of
Duchenne muscular dystrophy (DMD).
Methods and Findings: The levels of several subpopulations of circulating stem cells expressing the CD133 antigen were
determined by flow cytometry in 70 DMD patients. The correlation between the levels and clinical status was assessed by
statistical analysis. The median (6SD) age of the population was 10.6663.81 (range 3 to 20 years). The levels of
CD133+CXCR4+CD34- stem cells were significantly higher in DMD patients compared to healthy controls (mean6standard
deviation: 17.3861.38 vs. 11.061.70; P = 0.03) with a tendency towards decreased levels in older patients. Moreover, the
levels of this subpopulation of cells correlated with the clinical condition. In a subgroup of 19 DMD patients after 24 months
of follow-up, increased levels of CD133+CXCR4+CD34- cells was shown to be associated with a phenotype characterised by
slower disease progression. The circulating CD133+CXCR4+CD34- cells in patients from different ages did not exhibit
significant differences in their myogenic and endothelial in vitro differentiation capacity.
Conclusions: Our results suggest that levels of CD133+CXCR4+CD34- could function as a new prognostic clinical marker for
the progression of DMD.
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Introduction
The progression of Duchenne muscular dystrophy (DMD) is
characterized by a progressive impairment of muscle function
leading to death due to cardio-pulmonary failure in the late teens
or early twenties [1,2,3]. DMD exhibits a spectrum of muscle
disease, and clinical variability is observed regarding age of onset,
patterns of skeletal muscle involvement, heart damage, and rate of
progression. Unfortunately, most therapeutic strategies for DMD
have been palliative rather than curative. The reading frame
hypothesis has been proposed to explain the phenotypic
differences between Duchenne and Becker patients, as the DMD
phenotype results from deletions that shift the translational reading
frame while the BMD phenotype results from deletions that
maintain the translational reading frame. However, several
exceptions have been previously noted in the literature. Moreover,
among DMD patients, the clinical course of the disease and
response to steroid treatment cannot be entirely predicted
based on the type of mutation. This indicates that genotype
alone cannot predict disease progression, and that other genetic
or epigenetic factors determine the clinical expression of this
disorder [4–5]. The development of reliable prognostic markers
for the progression of the disease or response to treatment
would not only be advantageous for patient treatment, but also
help facilitate the evaluation of new experimental approaches in
DMD.
To date, several studies have attempted to identify prognostic
factors to predict the progression of DMD, and in this context,
patients have been clinically assessed based on cardiac and
pulmonary function measurements and their rate of decline [6–8].
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However, a precise assessment of clinical severity and prediction of
progression remains challenging. The levels of circulating
endothelial stem cells are considered a strong biomarker of
cardiovascular risk and have been recently used as a surrogate end
point in primary intervention studies of risk reduction [9–14]. In
addition, obstructive and restrictive lung diseases seem to be
associated with variations in the number of endothelial progenitor
cells in peripheral blood [15]. These studies are based on the
growing evidence that circulating endothelial progenitor cells
have the capacity to repair damaged endothelium and generate
new blood vessels in the tissue damaged area. Recently, we
identified a subpopulation of human circulating stem cells
expressing the CD133 antigen that can differentiate into
endothelial and muscle cell types [16]. These data confirmed
and extended the previous reports by Miraglia and Gallacher, who
characterized circulating CD133+ cells as having hematopoietic
and endothelial potential [17–18]. To test whether the levels of
circulating stem cells expressing the CD133 antigen could predict
the clinical severity and progression of DMD, we assessed stem cell
levels in DMD patients and analyzed the potential correlation with
clinical results.
Materials and Methods
Isolation and characterization of human CD133+
subpopulations from normal healthy and dystrophic
blood tissues
This study was approved by the ‘‘Ethical Committee of the
IRCCS Eugenio Medea Bosisio Parini’’. Blood was obtained
from 30 healthy volunteers (3–20 years of age) and 70 dystrophic
patients (3–25 years of age) after written informed consent
was obtained from each patient. Samples were obtained
from routine blood tests performed in healthy and DMD
subjects. Blood samples were diluted 1:3 in Iscove’s modified
Dulbecco’s medium (IMDM) (Gibco Life Technologies,
Grand Island, NY). The mononuclear cells were collected by
centrifugation (Ficoll-Hypaque, Pharmacia Biotech, Uppsala,
Sweden) and incubated with CD133-conjugated super paramag-
netic microbeads (monoclonal antibody, MoAb; CD133
Isolation Kit, Miltenyi Biotec, Bergisch-Gladbach, Germany).
Beads were washed and processed through a MACS
magnetic separation column (Miltenyi Biotec) to obtain
purified CD133+ cells. After selection, an aliquot of the CD133+
cell fraction was analyzed to assess purity, which was determined
for each isolation experiment. For four-color flow cytometric
analysis, 56104 cells were incubated with anti-CD133-phycoery-
thrin (PE) (Miltenyi Biotec), anti-CD34APC (Pharmingen), anti-
CXCR4-PECY5 (Pharmingen), anti-CDw90 (Thy-1)-fluorescein-
isotiocyanate (FITC, Pharmingen), anti-VEGFR(KDR)-FITC
(Pharmingen), anti-CD45-FITC (Becton Dickinson Immunocyto-
metry Systems, Mountain View, California, USA), as well as
with lineage antibodies against anti-CD3, CD4, CD8, CD14,
CD19, CD33, CD38 (all from Pharmingen). Isotype-matched
mouse immunoglobulin served as a control. Samples were
incubated at 4uC for 20 minutes, and cells were subsequently
washed in PBS containing 1% heat-inactivated FCS and
0.1% sodium azide. Cells were analyzed using a FACS
Calibur flow cytometer and Cell Quest software (Becton
Dickinson). Each analysis included at least 5000–10000 events,
and a light-scatter gate was defined to eliminate cell debris from
the analysis. The percentage of CD133+ cells was assessed after
correction for the percentage of cells reactive with the isotype
control.
GEArray gene expression and RT-PCR analysis of human
CD133+ cells isolated from normal and DMD blood
tissues
Total RNA was isolated from cells using the Trizol reagent
(Invitrogen) as described by the manufacturer. Aliquots of total
RNA (3 mg) were used for analysis of the human endothelial and
muscular gene expression profile with GEArray technology
(SuperArray Inc, Bethesda, MD) and RT-PCR analysis. The
biotin deoxyuridine triphosphate (dUTP)-labelled cDNA probes
were generated by the GEArray Ampolabeling-LPR kit. Random
primers were incubated with total RNA at 70uC for 3 min for
annealing, and samples were then reverse transcribed to cDNA at
37uC for 25 min. The cDNAs were amplified by PCR using gene-
specific primers and biotin 16-UTP (Roche). PCR was performed
according to the following protocol: 85uC for 5 min, 30 cycles of
85uC for 1 min, 50uC for 1 min, and 72uC for 1 min, and the final
step at 72uC for 5 min. After prehybridation, membranes were
incubated with biotin-labelled cDNAs overnight at 60uC;
membranes were then washed and blocked with GEAblocking
solution. The chemiluminescent detection was performed with
alkaline phosphatase-conjugated streptavidin and CDP-star sub-
strate, and visualized by exposure to electrochemilumiscence film.
Data were acquired with a scanner (Epson), the digital image was
converted to raw data file using the ScanAlyze Software, and the
acquired data were analyzed with GEArray Analyzer Software
(SuperArray). The expression level of each gene was compared to
the levels of the housekeeping gene glyceraldehyde 3-phophate
dehydrogenase (GAPDH) (3 spots in each array), whereas negative
values were transformed to zero. Expression of human myogenic
markers in CD133+ cells was also investigated by RT-PCR as
previously described [16]. Only samples positive for GAPDH
expression were considered, and we designed specific human
myogenic primers in unique regions based on deposited human
sequences. Total RNA was extracted from cells or muscles of mice
using the TrizolReagent according to the manufacturer’s protocol
(Gibco BRL, Life Technologies). First strand cDNA was prepared
using the Super Script First Strand Synthesis System for RT-PCR
(Invitrogen, Life Technologies) starting from 2 mg total RNA with
oligo(dT)12-18 priming. For direct amplification of human markers,
primers were specifically designed for regions of human sequences
that did not display homology with mouse mRNA sequences [16].
PCR was performed under the following conditions: 94u 5 min, 35
cycles at 94u for 40 sec, 68u for 40 sec, and 72u for 1 min.
In vitro myo-endothelial potential of the human CD133+
subpopulations from normal and dystrophic blood
tissues
CD133+ subpopulations isolated from normal and DMD blood
tissues were plated at a density of 105 cells/well in Falcon 6-well
tissue culture plates in proliferation medium (PM) consisting of
DMEM/F-12 (1:1), 20% FBS, HEPES buffer (5 mM), glucose
(0.6%), sodium bicarbonate (3 mM), and glutamine (2 mM). The
following cytokines were added to the PM: stem cell factor (SCF,
100 ng/mL; TEBU, Frankfurt, Germany), vascular endothelial
growth factor (VEGF, 50 ng/mL; TEBU) and leukemia inhibiting
factor (LIF, 20 ng/ml; R&D Systems, Inc). Cells were passed every
8 days. To determine the myogenic potential, CD133 positive-
derived cells were co-cultured with C2C12 murine myoblasts at a
ratio of 5:1 in differentiation medium (DM) consisting of Ham’s
F10 supplemented with 5% FBS, 10 ng/mL epidermal growth
factor (EGF), 10 ng/mL platelet derived growth factor (PDGF-B)
and antibiotics as previously described [16]. In these experiments,
the sorted subpopulations of human CD133+ cells derived from
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the blood of normal and DMD subjects were labeled according to
their expression of human lamin A/C. After 14 days of culture, the
presence of chimeric human/murine myotubes was evaluated by
immunostaining for desmin, slow myosin heavy chain (MyHCs)
and human lamin A/C. The percentage of differentiated
myotubes containing two or more nuclei expressing lamin A/C
(i.e., fusion index of the human blood-derived CD133+ cells) was
assessed. To determine whether CD133 positive subpopulations
exhibited endothelial stem cell characteristics, sorted normal and
DMD CD133+ cells were plated (,103 cells) in the presence of
M199 (Gibco BRL) supplemented with 20% FBS (HyClone),
vascular endothelial growth factor (10 ng/mL, Sigma), FGF
(5 ng/mL, human recombinant basic FGF; Sigma), heparin
(5 U/mL), penicillin (100 U/mL), streptomycin (100 mg/mL),
and fungizone (0.25 mg/mL). Cells were placed on 12-well plates
coated with 0.2% gelatin and incubated at 37uC in a humidified
environment with 5% CO2. This process resulted in the
attachment of mostly monocytes or mature endothelial colonies
on the plates. After 4 to 5 days, non-adherent cells were
transferred to other wells coated with 0.2% gelatin and grown in
endothelial growth medium. Endothelial colonies with tubule
formations were identified with primary mouse antibodies against
human Ve-cadherin (1:100; Becton Dickinson) and CD31 (1:100;
Chemicon) and visualized using an HRP-coupled secondary
antibody (Bio-Rad Laboratories) in PBS containing 0.6 mg/ml
diaminobezidine (Sigma Chemical Co). HUVECs were used as a
positive control for Ve-cadherin staining. Quantitative analysis of
total tubule formations expressing Ve-cadherin or CD31 antigens
was performed with the AngioSys software (TCS CellWorks, Cat
No. ZHA-1800).
Clinical evaluation and follow-up of DMD patients
All DMD patients included in the study were diagnosed by
clinical examination, muscle pathology, dystrophin analysis
(western blot) and immunohistochemistry, and screened for
mutations in the dystrophin gene. No patients were receiving
steroid drugs at inclusion in this study. Sixty patients were
evaluated; two were on ACE inhibitors and two were on carnitine.
Muscle strength was estimated by manual muscle testing using the
Medical Research Council (MRC) Scale. We tested the following muscle
groups: neck flexors and extensors, shoulder abductors, elbow
flexors and extensors, wrist flexors and extensors, trunk flexors and
extensors, hip flexors, extensors, abductors, adductors, ankle
flexors and extensors. As previously assessed [19], we then
calculated the total muscle strength (% MRC) as % MRC= sum
of grade score6100/number of muscles tested65. The assessment
of muscle strength of each subject was performed by two
physiotherapists with expertise in neuromuscular disorders.
Complete cardiac and respiratory evaluations were obtained from
physical examination, chest X-ray, electrocardiography, M-mode,
bidimensional and Doppler echocardiography and spirometry.
A clinical follow-up was performed in a subgroup of 19 patients
by repeating the entire assessment 12 and 24 months later.
Statistical analysis
Data were expressed as means6standard deviation (SD).
Comparisons between DMD and controls were analyzed by 2
tailed Student’s t-test (non-parametric) The univariate association
between the levels of CD133+CXCR4+CD34- and CD133+
CXCF4+CD34+ subpopulations with other variables was assessed
using linear regression analysis. The dependent variable in this
model was the continuous variable level of the subpopulation.
Independent variables included patient age, muscle strength, the
percentage of ejection fraction (EF%), and forced vital capacity
(FVC) values. A probability of less than 5% was considered
significant. These statistical analyses were performed using Prism
Graphpad 4.0 (Graphpad, CA, USA) software.
To identify predictors of changes in colony counts of endothelial
progenitor cells in a multivariate setting, we used multiple linear
regression (SPSS) on specific variables.
Results
Quantitative studies of CD133+ stem cells and correlation
with the DMD phenotype
CD133+ cells were isolated from a total of 70 patients with
Duchenne muscular dystrophy recruited during routine clinical
assessment at our Neuromuscular Centre; cells from 30 normal
subjects were analyzed as controls. The mean (6SD) age of
Duchenne patients was 10.6663.81 (range 3 to 25). The frequency
of mutations in the dystrophin gene in our DMD population was
as follows: 35 patients (50%) had a mutation in the central region,
9 (12.86%) a deletion in the amino terminal region, 11 (15.71%)
had other mutations (6 had deletions in the hot spot regions, 3 had
a point mutation, and 2 had a duplication); fifteen patients
(21.43%) had no identified mutations. We only analyzed the levels
of CD133+ cells in DMD patients not taking steroid medication.
Of the 70 patients, 12 had never initiated steroid therapy, while
the remaining patients had stopped steroid therapy prior to
assessment. CD133+ cells isolated from healthy subjects and DMD
patients were characterized for the expression of several stem cell
markers. Blood-derived CD133 positive cells represented less than
0.2% of the total mononucleated blood-derived cells in both
normal and dystrophic patients (range 0.04–0.1% in normal
samples and 0.06–0.2% in dystrophic samples). Hoechst 33342
staining of blood-derived CD133+ cells did not reveal the presence
of the SP fraction within these cells (data not shown). More than
98% of the normal and dystrophic blood-derived CD133+ cells
have a lineage negative phenotype (CD4-CD8-CD3-CD19-CD33-
CD38-). Further analysis of a set of surface markers, such as
CXCR4, CD34 and CD45, revealed these cells to be heteroge-
neous. In normal blood, 98% of CD133+ cells also expressed the
CD34 antigen, whereas approximately 83–90% of dystrophic
blood-derived CD133+ cells also expressed CD34. Moreover,
approximately 30–45% of CD133+ cells isolated from normal and
dystrophic blood tissues co-expressed CXCR4. Analysis of the
percent of CD133+CXCR4+CD34+ subpopulation did not reveal
any significant difference in DMD patients compared to healthy
controls (3.8760.63 in DMD subjects vs. 1.5862.39 in controls;
P = 0.12)(Fig. 1). Surprisingly, we observed that CD133+CXCR4+
CD34- cells were significantly increased in DMD patients
compared to healthy controls (17.3861.38 vs. 11.061.70;
P= 0.03)(Fig. 1). The percent of CD133+CXCR4+CD34-cells
did not show any significant variance among patients with
different mutations. We then analysed the levels of both
subpopulations among the different age groups of the DMD
patients and controls. Levels of CD133+CXCR4+CD34- cells
were consistently higher than the levels of CD133+CXCR4+
CD34- cells in both the DMD patients and controls, and tended to
decline with advancing age in DMD subjects (Fig. 2A and B). We
noticed that the levels of CD133+CXCR4+CD34- and CD133+
CXCR4+CD34+ cells were quite stable over time in the controls,
while in the DMD patients, the CD133+CXCR4+CD34- cells
peaked at the age of 9 (Fig. 2A). Linear regression analysis showed
a significant negative correlation between age and CD133+
CXCR4+CD34- levels (r2 = 0,056; P= 0.045)(Fig. 2C). Linear
regression analysis between the levels of circulating CD133+
CXCR4+CD34- cells and MRC% values showed that higher
Stem Cells as Biomarker
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levels of CD133+CXCR4+CD34- cells corresponded to higher
muscle strength (r2 = 0.065; P= 0.046)(Fig. 3A). The same
significant positive correlation was detected between percentage
of cells and EF (r2 = 0.065; P = 0.043) and FVC% (r2 = 0.089;
P = 0.025)(Fig. 3C and E, respectively).
Finally, multivariate regression analysis was performed to
determine whether the number of CD133+CXCR4+CD34- cells
was associated with age, MRC%, EF, or FVC%. This analysis
demonstrated that EF was an independent predictor of the
number of CD133+CXCR4+CD34- cells (P,0.001).
Analysis of clinical severity groups and disease
progression
To assess the predictive power of CD133+CXCR4+CD34- cell
levels, we investigated whether the levels of these cells correlated
with the course of the disease. We stratified the DMD patients into
two groups according to the results obtained from linear regression
analysis of age and levels of CD133+CXCR4+CD34- cells, and
then performed a detailed follow-up of 12 or 24 months on a
subgroup of 19 DMD patients. Of these patients, 8 were
categorized in the first group as exhibiting a percentage of
CD133+CXCR4+CD34- cells localized above the threshold level
for their corresponding age (mean age6SD: 9.1763.01), while 11
patients were in the second ground, showing values below the
regression line (mean age6SD: 10.9163.04). Five patients in the
first group and nine in the second completed the 24-month period
of observation. In the first group, 3 patients were wheelchair
bound at the beginning of the follow-up (patients were 8.8, 10.4,
and 13.4 years old). Five patients were still ambulant (2.9, 8.1, 9.4,
10.2 and 10.3 years), and of these, 2 lost ambulation during the
observation period at 10.5 and 10.9 years of age. Thus, the mean
age at loss of ambulation in this group was 10.0461.89. A
worsening of muscle strength was observed during the observation
period: the mean MRC% was 72.54614.02 at the onset (n = 8),
67.87616.97 after 12 months (n = 8), and 58.53612.99 after 24
months (n = 5)(Fig. 4A). At the beginning of the follow up, only one
Figure 1. CD133+ cells were isolated from the peripheral blood of 70 DMD patients and 20 age-matched control subjects and
analyzed by flow-cytometry. Representative panels show the CD133+CXCR4+CD34+ subpopulation in healthy subjects (mean percentage6SD,
1.5862.39 of total CD133+ cells) (upper right panel in A) and in DMD patients (3.8760.63)(lower right panel in B). A subpopulation of
CD133+CXCR4+CD34-cells was significantly increased in DMD patients (lower right panel in B) compared with healthy controls (lower right panel in
A) (mean percentage6SD, 17.3861.38 vs. 11.061.70 of total CD133+ cells). (C) Histogram showing the percentages of CD133+CXCR4+CD34+ cells of
healthy controls compared to DMD patients. (D) Histogram demonstrating the percentages of CD133+CXCR4+CD34- cells in healthy controls
compared with to DMD patients. *Significance (P , 0.05).
doi:10.1371/journal.pone.0002218.g001
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patient from the first group showed cardiac ECG abnormalities,
while echocardiographic findings were normal in all patients.
Spirometry measures indicative of a mild restrictive lung disease
were detected in 2 patients. During the follow-up, we observed a
preservation of cardiac and respiratory functions. In particular,
after 12 months, the spirometric analysis showed the appearance
of a mild restrictive pattern only in two patients. After the next 12
months, no further deteriorations were observed. The ECG
findings showed sinus tachycardia in one patient and conduction
abnormalities in another patient. Echocardiographic data re-
mained normal throughout the follow up. In the second group,
only one patient was still ambulant (4.8 years of age), and the other
patients had already lost the ability to walk independently. The
mean age at loss of ambulation was 10.2161.9. At the beginning
of the study, patients in group two had a mean age of 11.5263.4
(ranging from 9.5 to 14.8 years). The mean MRC% changed from
66.0968.5 (n = 11), to 57.4261.33 (n= 11), to 40.9766.22
(n = 9)(Fig. 4B). At the beginning of the observation period, 8
patients did not show cardiac abnormalities by ECG and
echocardiography assessments. Of these patients, 3 developed
ECG abnormalities, such as sinus tachycardia and conduction
abnormalities. Echocardiographic findings remained normal until
the end of the study (24 months for 2 patients and 12 months for
the third). Two patients had EGC abnormalities from the
beginning of the study: a complete right bundle branch block
and conduction abnormalities with no abnormalities at echocar-
diography in both cases until the end of the study. One patient
showed left ventricular regional wall motion abnormalities and
mitral valve prolaps from the outset. He then presented a rapid
deterioration of systolic function with an EF of 35% and treatment
with ACE inhibitors was initiated. Regarding respiratory function,
6 patients presented baseline normal spirometric characteristics. In
4 of these patients, the FVC remained within normal range values
until the last evaluation, while the other two showed a progressive
worsening and fall of the FVC that reached 45% predicted in one
patient and 50% predicted in the second after 24 months. In the
other 5 patients, at the outset of the study, a mild reduction in
spirometric variables and restrictive impairment was seen, which
increased until the end of the study (FVC range between 47% and
55%).
In a subgroup of 10 patients (n = 4 in the first group and n= 6 in
the second group), we repeated the analysis of the levels in the two
subpopulations at different times. The changes in CD133+
CXCR4+CD34- percentages for individual patients are shown
in Figure 4 (C and D). Throughout the study, the levels of
CD133+CXCR4+CD34- cells were significantly higher in the
group of DMD patients with a slow progressive disease course
(mean value6SD: 31.36%614.67% vs. 11.12%64.9%; P,
0.0001). Otherwise, the levels varied in a range of 7–55% in the
first group of patients with a mild course of disease, and between
3.6–21.95% in the second group of patients with severe disease
progression. We also observed great intra-individual variability in
two subjects of the first group in particular. These data suggest that
serial measurements of the CD133+CXCR4+CD34- cells (not less
than three) should be performed at standardized times for a
greater number of subjects.
Myo-endothelial potential and migrating phenotype of
blood-derived CD133 subpopulations isolated from
healthy controls and DMD patients
To determine whether the differences in the levels of circulating
CD133+CXCR4+CD34- stem cells observed in mild and severe
DMD patients correlate to a different myo-endothelial potential of
these cells, myogenic and angiogenic assays were performed. The
CD133+CXCR4+CD34- cells were sorted with a dual-laser
FACS Vantage SE (Becton Dickinson Immunocytometry Systems)
and the purity of cell sorting was confirmed as 98% in all
Figure 2. Levels of CD133+CXCD4+CD34- and CD133+CXCX4+CD34+ subpopulations are shown in DMD patients (A) and healthy
controls (B) stratified for age. Levels of CD133+CXCR4+CD34- cells were constantly higher than CD133+CXCX4+CD34+ cells in both DMD patients
and controls. DMD patients showed a nadir at the age of 4 years and one at the age of 9, with an overall tendency towards reduction with increasing
age. Linear regression analysis of DMD patient data revealed a significant negative correlation (r2 = 0.056; P = 0.045) between the level of
CD133+CXCR4+CD34- cells and age (C), while no significant correlation (r2 = 0.003; P = 0.63) between the level of CD133+CXCR4+CD34+ cells and age
was observed (D).
doi:10.1371/journal.pone.0002218.g002
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experiments. Using a human Stem Cell Gene Array, we found
that the CD133+CXCR4+CD34- sorted cells expressed genes
reflective of vascular progenitors, including CD31, FZD 2/3/4/7,
CXCR4, LIFR, and Notch promoter 1 (data not shown). To verify
the endothelial potential of sorted cells, the
CD133+CXCR4+CD34- cells from normal and dystrophic blood
were cultured in the presence of endothelial medium (End) as
indicated in Material and Methods. Under these conditions, we
observed the formation of colonies with spindle-like cells
expressing Ve-cadherin and CD31 endothelial markers from both
normal and dystrophic CD133+CXCR4+CD34- cell populations.
We also observed that in End culture, no colonies formed when
fewer than 300 cells/well were seeded, indicating the requirement
of cell–cell interactions in these conditions. Since circulating
CD133+ stem cells did not differentiate spontaneously into
myotubes in vitro [16], we investigated the expression of human
myogenic markers in normal and dystrophic sorted
CD133+CXCR4+CD34- cells co-cultured with C2C12 murine
myoblasts. RT-PCR analysis revealed the expression of M-cadherin,
Myf-5, Myogenin, Pax7, MyoD and MRF4 in normal and DMD
CD133+CXCR4+CD34- cells after 7 days of co-culture. The
myogenic rate of the CD133+CXCR4+CD34- stem cells was
similar in DMD patients (4.13%61.25% of the total human
lamins A/C positive cells per well; n = 10) compared to healthy
controls (3.82%60.9% of the total human lamins A/C positive
cells per well; n = 10), whereas the angiogenic rate of these cells
was selectively increased with no significant differences in mild
DMD patients (32.47%611.7% of the total human lamins A/C
positive cells per well; n = 10) versus healthy control subjects
(27.0%63.71% of the total human lamins A/C positive cells per
well; n = 10) and versus severe DMD patients (27.57%66.14% of
the total human lamins A/C positive cells per well; n = 10).
Figure 3. Correlation of CD133+CXCX4+CD34- and CD133+CXCX4+CD34+ subpopulations with MRC%, FE% and FVC% in DMD
patients. A positive correlation was observed between the level of CD133+CXCX4+CD34- cells and MRC percentage (r2 = 0.065; P = 0.046)(A), FE%
(r2 = 0.065; P = 0.043) (C), and FVC% (r2 = 0.089; P = 0.025) (E). No significant correlation was observed between the level of CD133+CXCX4+CD34+
cells and the above variables (B, D, and F).
doi:10.1371/journal.pone.0002218.g003
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According to our previous observations [20], blood-derived
CD133+ stem cells express several adhesion molecules involved
in cell migration through vessels into the skeletal muscle tissue. To
assess whether the circulating CD133+CXCR4+CD34- cells
isolated from normal and DMD patients were in a migratory
state, we analyzed them for the expression of molecules that are
expressed on the surface of stem cells with high migratory
capacity, as previously described [20]. The number of
CD133+CXCR4+CD34- cells with surface expression of L-
selectin or vascular cell adhesion molecule 1 (VCAM-1) was
markedly increased in DMD patients compared with healthy
controls (P,0.01 and P,0.001, respectively)(data not shown).
Moreover, the level of circulating CD133+CXCR4+CD34- stem
cells positive for these migratory markers was higher in patients
with mild phenotype than in patients with a severe condition, and
this showed a significant correlation with the clinical score
(r = 0.241, P,0.05)(data not shown). Negative linear regression
between the levels of circulating CD133+CXCR4+CD34- stem
cells expressing L-selectin and VCAM-1 and the age of DMD
patients was detected (r =20.145, P,0.05 and r =20.217,
P,0.05, respectively)(data not shown).
Discussion
Recent works from several laboratories have identified various
serum markers and cellular markers in predicting mortality and
morbidity in a wide variety of diseases, such as cardiovascular
disease and tumor pathologies [13–15,21–23]. In the field of
muscular dystrophies, no indicators have been identified thus far,
hence the importance of a finding a marker that may help identify
patients at increased risk for faster disease progression.
The main aim of our study was to determine whether the level
of circulating CD133+ stem cells was related to the disease status
of DMD. This finding would have a significant impact on patients’
treatment and management.
We selected a DMD population composed of subjects not
undergoing steroid therapy to avoid potential confusing variables.
Moreover, steroids are well known to influence the development,
differentiation and homeostasis of a large number of cells. In
particular, glucocorticoids (GC) affect the differentiation of several
types of stem cells such as mesenchymal [24] and neural stem [25]
cells in vitro, and also have an effect on the proliferation and
maturation of human peripheral blood stem cells in vitro and in vivo
Figure 4. Representation of 2 different disease courses in 19 DMD patients stratified into 2 groups, in which a 24-month follow-up
was available according to the results obtained from linear regression analysis between age and levels of the
CD133+CXCR4+CD34- cells. MRC% scores are shown over time in 8 patients with a percentage of the cells localized above the threshold
level for the corresponding age (A and C) and in 11 patients with values below the regression line during a total follow-up period of 24 months (B
and D). At the end of the observation period, in the first group of DMD patients, the mean MRC% decreased by approximately 14%, and the total
clinical score approximately 2.25 points. In the second group, the MRC% decreased by approximately 25%. In a subgroup including 4 DMD patients of
the first group and in 5 DMD patients of the second group, we measured CD133+CXCR4+CD34- cells levels. Differences between the baseline values
of CD133+CXCR4+CD34- cells and those at 2, 4, 6, 12 and 24 months are shown for individual patients in E and F. Despite the significant increase of
CD133+CXCR4+CD34- cells compared to the patients of the second group (mean value6SD: 31.36%614.67% vs. 11.12%64.9%; P,0.0001), the 4
patients in group 1 displayed major intra-individual variability between successive measurements.
doi:10.1371/journal.pone.0002218.g004
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[26]. The migratory capacity and relative baseline levels of
CD133+ cells may be influenced by chronic steroid therapy. In
fact, as we recently demonstrated [20], CD133+ stem cells express
several adhesion molecules, such as CD44, LFA-1, PSGL-1, a4-
integrins, L-selectin, and chemokine receptor CCR7, that provide
the physical connection with the activated endothelium in the
DMD inflamed muscle. Steroids could affect the interaction
between CD133+ cells and the endothelium due to their anti-
inflammatory action on the DMD muscle or cause a direct change
in the expression of surface adhesion molecules on CD133+ cells.
Analysis of the number of circulating CD133+ cells from the
peripheral blood of DMD patients revealed an interesting course
of the CD133+CXCR4+CD34- subpopulation. We found that the
percentage of CD133+CXCR4+CD34- cells was increased in
DMD patients compared with healthy controls. The mean
levels of CD133+CXCR4+CD34- in DMD subjects showed a
tendency to decrease with advancing age, although there were
two nadirs between the ages of 4–5 years and 11–12 years. Both of
these ages correspond to a crisis in Duchenne muscles
resulting in the onset of symptoms in the first time period and
the loss of independent ambulation in the second period. Our
hypothesis is that the circulating levels of CD133+ cells at these
particular stages are lower as a result of a major homing in the
injured muscle.
The clinical severity of each patient was assessed by manual
muscle testing and respiratory and cardiac function measurements.
From the literature, particular consideration has been given to
monitoring muscle strength and the functional abilities of DMD
patients, and several standardized scales have been developed
[19,27]. However, in order to determine the clinical status and the
extent of the disease progression, it is also important to assess, as
objectively as possible, cardiac [28–30] and respiratory function.
Pulmonary function assessment, such as forced vital capacity
(FVC), is an acknowledged clinically relevant endpoint and the
rate of decline in FVC was found to be useful in predicting the life
expectancy of DMD patients [7,8]. Linear regression analysis
showed a positive correlation between the levels of circulating
CD133+CXCR4+CD34- cells and muscle strength, EF% and
FVC% in DMD patients. A strong correlation was also confirmed
between the levels of circulating CD133+CXCR4+CD34- cells
and the rate of disease progression. In fact, the levels of
CD133+CXCR4+CD34- cells were greater in DMD patients
with a slow progressive course compared to DMD patients
who showed a rapid disease course. Multivariate analysis
between the number of CD133+CXCR4+CD34- cells and
MRC%, FE% and FVC% confirmed that all these variables are
predictors of the number of CD133+CXCR4+CD34- cells, with
FE% as the best predictor. These data suggest that the levels of
circulating CD133+CXCR4+CD34- cells could be a biomarker
for DMD.
Moreover, we observed that the nature of the dystrophin gene
mutation did not affect the levels of both CD133+CXCR4+CD34-
and CD133+CXCR4+CD34+ cells in the DMD subjects analyzed
in this study. In fact, comparison of patients based on the genetic
mutation did not reveal any significant difference with respect to
the percentage of these two subpopulations.
The nature and size of our study does not permit us to
determine whether low levels of CD133+CXCR4+CD34- cells
can accurately predict the progression of disease. On the other
hand, for disorders in which the patient population is small, it is
critical to obtain reliable data working with a small sample size.
Further research will need to focus on determining the precise
clinical relevance of the level of CD133+CXCR4+CD34- cells,
and if and how these correlate with quality of life, time of death,
and other life-changing events (e.g., using a wheelchair). In this
study, we also investigated the myogenic and endothelial potential
of CD133+CXCR4+CD34- cells isolated from the peripheral
blood of healthy and DMD subjects. Freshly isolated
CD133+CXCR4+CD34- cells from normal and dystrophic blood
express several myogenic and endothelial markers, suggesting
similar myo/endothelial potential. Moreover, the CD133+
CXCR4+CD34- cells derived from the DMD blood cultured in
the presence of endothelial medium give rise to a higher number of
endothelial colonies than those from the normal counterpart,
indicating that these cells probably receive more specific signals for
endothelial differentiation from DMD tissues. There are several
possibilities that might account for the increase in angiogenic
capacities of this subpopulation of CD133+ stem cells. First, it has
been established that endothelial progenitors can be mobilized
from the bone marrow to blood in response to a variety of
inflammatory cytokines like those released in dystrophic skeletal
muscle tissues, which could explain the increased levels of
CD133+CXCR4+CD34- stem cells in DMD patients. Indeed,
previous studies have suggested that activated endothelial
progenitors express several adhesion molecules, such as E-selectin
and VCAM-1 [31], involved in the migration from the blood.
Moreover, we previously demonstrated that VCAM-1 blockade
prevents blood-derived CD133+ accumulation in dystrophic
muscle and that the VCAM-1-VLA-4 adhesion receptor pair has
a critical role in the recruitment of these stem cells to dystrophic
muscle vessels [16]. For these reasons, we stratified the
subpopulations of circulating CD133+ stem cells based on the
expression of several adhesion molecules. We found that the
number of CD133+CXCR4+CD34- cells with surface expression
of L-selectin and VCAM-1 was markedly increased in DMD
patients compared with healthy controls and with a preponder-
ance of these cells in patients with a mild phenotype. Moreover,
the levels of CD133+CXCR4+CD34- cells expressing L-selectin
and VCAM-1 decrease with age and course of the disease. We
believe all these data suggest that the circulating
CD133+CXCR4+CD34- stem cells have a principal role in the
vascular homeostasis of the dystrophic skeletal muscle and may
partially contribute to muscle regeneration. We further speculate
that continuous muscle degeneration of dystrophic muscles may
lead to progressive injury of muscle fibers and vessels with
consequent depletion of these myo/endothelial circulating pro-
genitor cells. Future studies will therefore be needed to determine
whether this postulated muscle-vessel injury–induced exhaustion
of circulating myo/endothelial progenitor cells is a factor in the
pathogenesis of Duchenne muscular dystrophy disease.
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